Member Info for carlotowl

I think the muted rise today is a result of all the missed timelines and a lack of trust in the new timelines. The RNS is massive and the enlightened of us can see what lies ahead. Avacta is going to ne huge, you've just got to be patient.

I'd just like to point out that Myles and Ophidian predicted this. For all those that dislike them both, it seems they were spot on.

GAD is a manufacturing spin off created by Mologic, but isn't actually Mologic.

"Bedfordshire, UK, 24 APRIL 2020: Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, disclosed today that work is well underway on a new diagnostic manufacturing facility adjacent to the firm’s current laboratory in Bedfordshire, UK.

The facility has been incorporated as an independent, sustainable social enterprise under the name of Global Access Diagnostics, with a commitment to deliver diagnostics at a fair price to both national and international markets."

It's also interesting that other than Surescreen it's only manufacturers that are mentioned by name. The word 'Mologic' is no where to be seen yet they are the owners of the test that ODX and Global Access Diagnostics will make.

Chill people. As others have stated they are just banking profit as they bought in at the placing at 0.45p and have made around 500%. I did exactly the same when we hit 2.3p as my average is 0.58, it's just sensible investing. SP should get a leg up now if they've finished selling but I don't think it'll pop above 3p without further news. We'll see.

Still obsessing with Myles I see Mortgage.....

The fact that Abingdon, Omega, BBI, Mologic and Avacta aren't on this list speaks volumes about the theory that something separate is coming for those companies. Actually more confident now. Also, as pointed out, it was awarded ages ago.

I find it astounding that the hype around ODX isn't translated over here. Lead UKRTC member, more manufacturing capacity, and partnering with more antigen test makers (= more shots on goal).

One last post on the matter. Their stated aim in the admission document is to be able to produce 150 million LFT's per annum. That's 2.88 million a week.

They do say in their admission document that by the end of 2020 they could manufacture 1 million LFD's a week, but don't go any further. But as I said, if ODX can do 500k per week now and ate looking at 2 million a week by April I would expect Abingdon to at least match that, more likely exceed it. They have a £100 million pipeline so thr MCAP on confirmation of the manufacture of the rapid antigen will be a lot more than it currently is.

No I don't know with any certainty, that number is shouded in mystery. However back in June last year when Abingdon reported an expansion in Lateral Flow manufacturing capability they stated they could make 'millions' of tests per month, which to me suggests more than 2 million, so at least 500,000 per week (which at the time was the most in Europe's from any one company). Since then the govt has been assisting UKRTC members to ramp up and the govts stated aim is 2 million tests per day (14 million a week) of which ODX could only make 2 million. There are only 3 other members of the RTC, so if you take out ODX's known capacity of 2 million a week that leaves 12 million a week more to be manufactured by the other 3 members of the RTC. Divide 12 million by 3 and it equals 4 million per manufacturer. Assuming Abingdon has been ramping up in a similar way to ODX (not an unreasonable assumption since the IPO specifically stated the £22 million raised will be used to increase LFD manufacturing capacity), it stands to reason that they will remain the company capable of manufacturing the largest amount of LFD's for thr govt.

This stock is flying under the radar currently. Very low risk here imo with the UKRTC rapid test plans leaked with Abingdon a known part of it. They will manufacture whichever test makes the grade and are the biggest LFT manufacturer in Europe. ODX might make a bit more money per test but I don't think they'll have the capacity Abingdon do and the IPO was done for this very reason. Should at least be equal to ODX MCAP imo but just hasn't been hyped up yet like ODX has ben for months. Next week it'll re rate.

You are overly negative Wolves, but I like to be reminded of the risks personally. Also, the SP today so far seems to be proving that despite uber rampers best efforts, big rises on no news don't seem to be sustained without a confirmatory RNS. Just need to stick by our research here - it's more obvious than ever that it's more likely than not going to happen. If not, I'll wait for Pre Cision.

HL will take my 109k shares @ 123p.

Spot on Wolves. I personally will continue to hold because as has been said many times, there are too many coincidences and breadcrumbs alongside the vague info provided by the company to think it has/will fail on the Covid front. That's not to say I'm not getting nervous at the lack of info. I stand by my research and convictions because imo it will pay-off in the short, medium and long term and make me a millionaire.

You may be right DOH, but this is AIM. You've been here long enough to know many PI's don't react to things rationally.

There doesn't appear to be lots of 'we've missed the boat' panic selling to do with the Surescreen contract which is good news.

Arnold, he did allude to Covid tests. "I look forward to updating the market on further progress on these and the diagnostic programmes across the Group in the near term."

This is huge news. Yet more validation of Avacta technology, upfront revenue, faster proof of the safety and effectiveness of the platform, ongoing revenue through milestone payments and royalties. On any other day this would be regarded as a big RNS by the market, but I suspect we'll see a small rise as is not covid test related. Sad really that every is so obsessed with covid.

And to think, someone on the ODX board posted that MB would have the grace to admit he was wrong. Very much clutching at straws with your take on last night's snippet of info. IMO ODX are readying for production of Avacta's test as well as BBI and Abingdon. And judging by the SP movements this morning, the market agrees.